Han Kun represents QL Biopharm in establishing collaboration with Tonghua Dongbao on its GLP-1 Semaglutide Injection product
May, 2024 - Beijing, Mainland China
Recently, Beijing QL Biopharmaceutical Co., Ltd. ("QL Biopharm") and Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao") entered into a collaboration agreement, according to which Tonghua Dongbao will obtain exclusive commercialization rights in the Chinese mainland for QL Biopharm's GLP-1 product, Semaglutide Injection (indication: glycemic control in adult patients with type 2 diabetes). In addition, the two parties will collaborate on developing the product in overseas markets.
In recent years, GLP-1 products have demonstrated significant value in the treatment of diabetes and weight management. The GLP-1 product in this collaboration is Semaglutide, a long-acting GLP-1 analogue. The partnership between QL Biopharm and Tonghua Dongbao aims to bring the internationally leading Semaglutide to a larger number of domestic diabetes patients. The collaboration in overseas markets is also an important step in the product's international market strategy, which is further opening up broader overseas opportunities and benefiting patients worldwide.
Han Kun is representing QL Biopharm in its collaboration with Tonghua Dongbao regarding the GLP-1 product. Owing to the firm's extensive experience and profound understanding of the life sciences industry, Han Kun not only provided legal services throughout all stages of the transaction process, such as deal structure design, contract negotiation, and project consummation, but was deeply involved in negotiating commercial terms for the strategic cooperation, which requires a high level of specialized expertise. This project is an excellent example of Han Kun's experience and expertise in the life sciences and healthcare industry.
About QL Biopharm
QL Biopharm focuses on the production of recombinant protein drugs using Escherichia coli, and is committed to the development of innovative biological drugs for the treatment of chronic metabolic diseases (such as diabetes, obesity, NASH, etc.) to improve the quality of life. At present, ten innovative recombinant protein drugs and biosimilars are in current QL Biopharm R&D pipeline. The core members of QL Biopharm's R&D team come from Novo Nordisk and other well-known pharmaceutical companies around the world, and have accumulated rich experience in biopharmaceutical field.
